A Unicenter Cross-Sectional Study of Cancer Patients data admitted at Urmia Milad Hospital: Pathobiological and Demographic Findings
Abstract
Objectives: Cancer is one of the most prevalent diseases in Iran and worldwide. Epidemiological studies indicate a rising incidence of cancer. This study aimed to evaluate the clinical, demographic, and pathobiological findings in cancer patients admitted to Urmia Milad Hospital.
Methods: The records of all patients hospitalized between 2019 and 2023 were reviewed and analyzed. Examined variables included age, gender, pathology and laboratory reports, and primary complaints. The exclusion criteria for the study were incomplete records or insufficient data.
Results: The mean age of female patients was significantly lower than that of male patients. Breast and bladder cancers were the most commonly referred cancers, whereas laryngeal and cervical cancers had the lowest frequency.
Conclusion: The findings of this study indicate that disease patterns, primary complaints, laboratory findings, and pathology characteristics in patients share both similarities and differences with nternational trends. It should be noted that this single-center study does not provide a comprehensive picture of cancer statistics in the province, though it offers valuable insights into current conditions.
2. Rathmell WK. Using the national cancer plan to drive innovation in cancer research. Cancer Discovery. 2024;14(4):555-8.
3. Kim HI, Lim H, Moon A. Sex Differences in Cancer: Epidemiology, Genetics and Therapy. Biomol Ther (Seoul). 2018;26(4):335-42.
4. Danaei M, Haghdoost A, Momeni M. An epidemiological review of common cancers in Iran; a review article. Iranian Journal of Blood and Cancer. 2019;11(3):77-84.
5. Gretzer MB, Partin AW. PSA levels and the probability of prostate cancer on biopsy. European Urology Supplements. 2002;1(6):21-7.
6. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-e203.
7. Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2023;22(2):93-104.
8. Zahed H, Feng X, Sheikh M, Bray F, Ferlay J, Ginsburg O, et al. Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study. International journal of cancer. 2024;154(1):28-40.
9. Gupta S, Gupta A, Saini AK, Majumder K, Sinha K, Chahal A. Prostate cancer: how young is too young? Current urology. 2015;9(4):212-5.
10. Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent? Biochimie. 2023;213:130-8.
11. Keim-Malpass J, Vavolizza RD, Cohn WF, Kennedy EM, Showalter SL. Cancer screening and treatment delays during the COVID-19 pandemic and the role of health literacy in care re-engagement: Findings from an NCI-Designated Comprehensive Cancer Center sample. Journal of Cancer Education. 2023;38(5):1405-12.
12. Schwartz SM. Epidemiology of cancer. Clinical chemistry. 2024;70(1):140-9.
13. Taheri Soodejani M. Five Common Cancers in Iran in 2019: Secondary Analysis to Discovering Cluster of Cancers. Journal of Primary Care & Community Health. 2023;14:21501319231186923.
14. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iranian journal of public health. 2018;47(3):309.
Files | ||
Issue | Vol 2 No 3 (2024) | |
Section | Original Articles | |
DOI | https://doi.org/10.18502/abi.v2i3.19098 | |
Keywords | ||
Urmia laboratory findings Age Sex Cancer |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |